Environmental Monitoring in Pharmaceutical Cleanrooms: Methods, Limits and Frequency

Environmental monitoring (EM) is the routine sampling of air, surfaces and personnel in cleanrooms to show that microbial and particle contamination stays under control. In sterile manufacturing it is one of the main sources of evidence that aseptic conditions are maintained, alongside process simulation (media fills) and sterility testing.

This guide covers EM methods, the limits in EU GMP Annex 1 (2022) and the FDA aseptic processing guidance, the contamination recovery rate approach of USP <1116>, sampling frequency, and how excursions are handled. For cleanroom classes themselves, see ISO 14644-1 cleanroom classification and cleanroom grades vs ISO classes.

Environmental monitoring at a glance

ItemSummary
PurposeShow that cleanroom conditions stay within limits during operation and detect trends or loss of control early
What is monitoredTotal (non-viable) airborne particles, viable airborne microorganisms, surfaces, personnel (gloves and gowns), and utilities such as water and compressed gases
Main viable methodsActive air sampling, settle plates, contact plates, swabs and glove prints
Key guidanceEU GMP Annex 1 (2022), FDA aseptic processing guidance (2004), USP <1116>, ISO 14644-2 for particles
Grade A expectationNo growth; any growth is investigated
Basis of the programmeA documented, risk-based contamination control strategy

Viable and non-viable monitoring

  • Non-viable (total particle) monitoring counts all airborne particles, usually at ≥0.5 µm and ≥5 µm, with particle counters. In Grade A it is continuous for the full duration of critical processing.
  • Viable monitoring detects living microorganisms that grow on culture media. Results are in colony-forming units (CFU) and take several days.

Both are needed: particle counts give immediate information, while viable results show what is actually present.

Environmental monitoring methods

MethodWhat it samplesTypical formatResult unit
Active air samplingA measured volume of air drawn onto agarImpaction samplers, commonly 1 m³ per sample in critical areasCFU/m³
Settle platesMicroorganisms settling from the air over time90 mm plates, exposed for up to 4 hours eachCFU/4 hours
Contact platesFlat surfaces55 mm RODAC plates pressed onto the surfaceCFU/plate
SwabsIrregular or hard-to-reach surfacesSwab rinsed into diluent and platedCFU per swab or area
Glove printsOperator glovesFive fingertips pressed onto a plateCFU/glove
Gown samplingOperator garmentsContact plates on defined gown sitesCFU/plate

Media for viable monitoring are usually general-purpose media such as soybean–casein digest agar (TSA), often with neutralizers to counter disinfectant residues. Incubation conditions, such as a two-temperature sequence to recover both bacteria and fungi, should be justified by recovery studies. Settle plate exposure time should also be based on recovery studies so that the medium does not dry out.

EU GMP Annex 1 (2022) microbial limits

GradeAir sample (CFU/m³)Settle plates, 90 mm (CFU/4 hours)Contact plates, 55 mm (CFU/plate)Glove print, 5 fingers (CFU/glove)
ANo growthNo growthNo growthNo growth
B10555
C1005025–
D20010050–
Maximum action limits for viable contamination, EU GMP Annex 1 (2022), Table 6. Settle plates can be exposed for less than 4 hours; they are changed as required after 4 hours.

In Grade A, any growth should lead to an investigation. Annex 1 also expects continuous viable air monitoring in Grade A, for example by air sampling or settle plates, for the full duration of critical processing, including aseptic equipment assembly.

FDA aseptic processing guidance (2004) action levels

ISO class≥0.5 µm particles/m³Active air action level (CFU/m³)Settle plates, 90 mm, 4 h (CFU)
ISO 53,52011
ISO 635,20073
ISO 7352,000105
ISO 83,520,00010050
Recommended levels from the FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing (2004), Table 1. The FDA notes that alternative levels may be appropriate.

USP <1116>: contamination recovery rates

USP <1116> is an informational chapter. Instead of focusing only on CFU counts, it recommends tracking the contamination recovery rate: the percentage of samples that show any growth.

EnvironmentActive airSettle plate (9 cm, 4 h)Contact plate or swabGlove or garment
Isolator or closed RABS (ISO 5 or better)<0.1%<0.1%<0.1%<0.1%
ISO 5<1%<1%<1%<1%
ISO 6<3%<3%<3%<3%
ISO 7<5%<5%<5%<5%
ISO 8<10%<10%<10%<10%
Suggested initial contamination recovery rates, USP <1116>. Rates should be based on actual monitoring data and re-tabulated regularly.

For example, if 300 active air samples in an ISO 5 zone over a period give growth on 2 samples, the recovery rate is 2 ÷ 300 = 0.67%, which is below the suggested 1%.

How often to sample

Sampling frequency is set by risk and by the grade of the area. Typical expectations are:

  • Grade A (ISO 5) critical zones: continuous particle monitoring and continuous viable air monitoring for the full duration of critical processing; glove prints at the end of each critical operation or session.
  • Grade B (ISO 7 in operation) backgrounds: monitoring during each operating shift or session, with frequency and sample size enough to detect changes.
  • Grade C and D areas: frequency based on quality risk management, the process and historical data.

USP <1116> gives examples, such as sampling ISO 5 and ISO 7 aseptic processing areas each operating shift. The final programme should be justified in the site contamination control strategy.

Setting alert and action levels

  • Action levels are the maximum limits (for example Annex 1 Table 6). Exceeding them requires investigation and corrective action.
  • Alert levels are set below action levels, usually from historical data, to give early warning of a drift.
  • Trends matter as much as single results: repeated low counts at the same location, a change in the organisms recovered, or a rising recovery rate can signal loss of control before a limit is exceeded.

Handling an excursion

  1. Confirm the result and check for laboratory error (media, handling, incubation).
  2. Identify the microorganism, at least to genus and preferably to species in Grade A and B.
  3. Assess the impact on product made during the period, including batch records, interventions, and other EM and process data.
  4. Investigate the likely source (personnel, surface, air supply, materials) and look at trends.
  5. Define corrective and preventive actions, such as retraining, cleaning changes or engineering fixes, and check their effectiveness.

Common mistakes in environmental monitoring

  • Sampling only in easy locations rather than at points of highest risk near open product.
  • Sampling after cleaning instead of during operations.
  • No neutralizer in media where disinfectant residues are present.
  • Settle plates exposed too long so the agar dries out.
  • Treating counts below the action level as “passes” without looking at trends or organism types.
  • Disturbing unidirectional airflow while sampling in Grade A.

Frequently Asked Questions (FAQs)

What is environmental monitoring in pharmaceutical microbiology?

A planned programme of sampling air, surfaces and personnel in cleanrooms to show that contamination remains under control during manufacturing.

What is the limit for settle plates in Grade A?

No growth, under EU GMP Annex 1 (2022). Each 90 mm plate is exposed for up to 4 hours, and any growth in Grade A is investigated.

What is the difference between settle plates and active air sampling?

Active air sampling draws a known air volume and gives CFU/m³. Settle plates passively collect microorganisms that fall onto the agar over time and give CFU per plate per exposure time.

What is a contamination recovery rate?

The percentage of environmental samples that show any microbial growth, as described in USP <1116>. For ISO 5 areas the suggested initial rate is below 1%.

Which media are used for environmental monitoring?

Usually soybean–casein digest agar (TSA), often with neutralizers such as lecithin and polysorbate 80, and growth-promotion tested before use. See also sterility testing (USP <71>) for the media used in product testing.

References

  • European Commission, EudraLex Volume 4, Annex 1: Manufacture of Sterile Medicinal Products (2022).
  • U.S. FDA, Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice (2004).
  • USP General Chapter <1116> Microbiological Control and Monitoring of Aseptic Processing Environments.
  • ISO 14644-2:2015, Monitoring to provide evidence of cleanroom performance related to air cleanliness by particle concentration.

This guide is for education. Use the current official guidance and your approved procedures.

Leave a Comment

Your email address will not be published. Required fields are marked *